Background: In march 1997 an international workshop introduced a new International Prognostic Scoring System (IPSS) for MDS. The goal of the present study was to apply the IPSS to a large group of MDS patients from one centre and to compare it to the FAB-classification.
Introduction
Since its introduction in 1982 the French-AmericanBritish Classification (FAB) [1] has been extensively applied to subtype the Myelodysplastic Syndromes (MDS). Although it has proven to be a valid tool in clinical practice, the classification has several shortcomings concerning its use in evaluating clinical outcome for MDS patients. Firstly, the FAB-proposal completely relies on the bone marrow (BM) and peripheral blood blast counts while many studies have suggested the prognostic importance of other morphological, clinical and biological variables [2] [3] [4] [5] [6] [7] [8] [9] . Secondly, for the RAEB and the CMML subtypes a wide range of BM blasts is used. Thirdly, there are significant differences in clinical outcome among patients belonging to the same FABsubtype.
These problems have led to the development of numerous additional classification systems [2] [3] [4] 10] but their clinical usage is still debated.
To improve the prognostic utility of these systems, an international workshop combined data of MDS patients of seven previously reported studies [2] [3] [4] [10] [11] [12] [13] and analyzed these data centrally. The major variables found to be significantly influencing clinical outcome were BM blast count, number of cytopenia and cytogenetic abnormalities. A multivariate analysis resulted in the design of the International Prognostic Scoring System (IPSS) [14] .
The purpose of the present study was to apply the IPSS on a group of 184 primary MDS patients diagnosed in our institution with a median follow-up of 6.5 years and to evaluate its usefulness in predicting clinical outcome for MDS patients.
Patients and methods

Patients
One hundred eighty-four MDS patients diagnosed and followed up at the University Hospital of the K.U. Leuven, Belgium, between 1980 and 1997 were selected. Only patients who underwent bone marrow biopsy at the time of diagnosis were included, as we aim to correlate the results of the present study to the findings of the bone marrow histology (study under investigation). Further we used similar selection criteria as used by the IPSS workshop [14] : therapy related MDS cases were not included, CMML cases with white blood cell counts > 12 x 10 3 /ul were also excluded because of the proliferative nature of these cases. However, patients were diagnosed during a different time period as compared to the workshop patients: our group contained a high proportion of patients diagnosed during the last seven years (102 of 184 patients). Several of these patients (30 of 102 patients, 29%) were treated with high-dose chemotherapy while none of the patients of the 1603 medium supplemented with fetal calf serum, penicillin and glutamin for 24 or 48 hours without stimulation and synchronized using methotrexate and BRDU. Metaphases were obtained after colcemid treatment and R-banded with acridin orange. Selected cases were also G-banded with Wright's stain to clarify abnormalities. Karyotypes are described according to the International System for Human Cytogenetic Nomenclature [16] .
Calculation of prognostic risk according to the IPSS Prognostic risk was calculated as proposed by the IPSS study group [14] and as outlined in Table 2. workshop study received such therapy. Therefore we divided our patients into two groups diagnosed respectively before (82 patients, 45%) and after I January 1991 (102 patients, 55%), the year in which high-risk MDS patients were systematically treated with AML-like protocols. We performed statistical analysis on both overall and separated groups.
Eighty-eight patients were already included in previous studies [5, 15] .
Patient characteristics are summarized in Table 1 and compared to those of the IPSS workshop patients, using chi-square tests.
Morphological analysis
Patients were diagnosed and subtyped based on morphological examination of peripheral blood and bone marrow smears. Dysplastic features and the bone marrow blast count were evaluated as proposed by the FAB-group [1] . Non-proliferative CMML patients had WBC counts <12 x 10 3 /ul, as well as other features of MDS, and were included in this analysis. Proliferative CMML patients were excluded.
AML-evolution
Of 177 patients, data concerning AML evolution were known. Times for progression to AML were known for only 21 of the 49 patients who evolved to AML. No Kaplan-Meier statistics were performed for AML-evolution.
Statistical analysis
Patients' baseline characteristics are compared to those used for the IPSS workshop using chi-square tests. The tests use the total number of patients to correct for the sample size difference. The results of those tests should be interpreted as indications for difference between the characteristics of the two patient samples. The survival probabilities are summarized and plotted using Kaplan Meier estimates. Based on the same method median survival and median follow-up are estimated. Two sided Log rank tests were used wherever the survival of patient groups were statistically compared. Tests are considered significant when the /'-values are less than 0.05.
Cytogenetic analysis
Cytogenetic analysis was performed on the bone marrow samples taken at the time of diagnosis, according to standard techniques. In cases where this was unsuccessful, the nearest successful karyotype was used for this study. In 21 cases a karyotype obtained longer than one year after diagnosis was used. In short, cells were cultured in RPMI
Results
The separation of all 184 patients into MDS-subgroups according to the FAB-criteria and the distribution of patients between different groups for each single variable found by the workshop to be significant are shown in Table 1 . Comparison with the IPSS workshop patients is made.
The proportions of patients within the four prognostic categories as defined by the IPSS are: 22% (40 patients) in the low-risk group, 46% (85 patients) in the INT-1-risk group, 25% (46 patients) in the INT-2-risk group and 7% (13 patients) in the high-risk group. As illustrated by Figure 1 , these four groups show significantly different clinical outcomes with respect to survival (P = 0.0001). Median survival of the low-risk group was 6.5 years, 2.6 years for the INT-1-risk group, 1.3 year for the INT-2-risk group and 0.7 year for the high-risk group.
Effect of time period of diagnosis
After stratification of patients by the time of diagnosis (< 1991 and 2=1991), separation into the four IPSS categories remained well for both groups but survival data differed substantially. Patients of the 'early' group showed shorter median survivals in comparison to patients of the 'late' group: 5.2 vs. 6.6 years for the low-risk group, 2.0 vs. 3.0 years for the INT-1-risk group, 0.5 vs. 0.8 years for the high-risk group. There was no difference in survival in the INT-2-risk groups. In addition, patients who were treated with AML type therapy were predominantly present in the INT-2-risk group (11 of 28 patients, 39%) and the high-risk group (6 of 7 patients, 86%). Eleven percent of the low-risk (2 of 19 patients) and 25% of the INT-1-risk group (12 of 48 patients) had received high-dose chemotherapy.
Effect of age
Patients were also stratified by age into the four IPSSrisk groups. Proportions of patients and corresponding survival data are summarized in Table 3 .
Patients younger than 60 had better median survival times when stratified into the low-risk, INT-1-risk or high-risk groups, compared to patients older than 60. This phenomenon was not evident for patients in the INT-2-risk group. Figure 2 shows survival of patients related to their FAB classification subgroup. The FAB also discriminates effectively with respect to survival but appliance of the IPSS within each single FAB-subgroup revealed a more sensitive discrimination. RA patients (58 patients) were present in the low-risk, INT-1-risk and INT-2-risk subgroups (35%, 55% and 10%), RARS patients (23 patients) were separated into the low-risk and INT-1-risk subgroups (48% and 52%). RAEB patients (53 patients) were distributed predominantly between the INT-1-risk (49%) and INT-2-risk (45%) prognostic groups, RAEB-t patients (23 patients) between the INT-2-risk (44%) and high-risk (48%) subgroups. CMML patients (27 patients) were present in the low-risk, the INT-1-risk and the INT-2-risk group (26%, 52%, 22%). 
FA B-classification
Risk of AML evolution
Of the 177 patients analyzed for AML evolution, percentages of patients who evolved to AML (49 of 177 patients) for each IPSS subgroup were as follows: 16% in the low-risk group (6 of 37 patients), 26% in the INT-1-risk group (21 of 81 patients), 30% in the INT-2-risk group (14 of 46 patients) and 62% in the high-risk group (8 of 13 patients). Mean times for progression to AML for those who actually evolved to AML were 28 months for the INT-1-risk group, 10 months for the INT-2-risk group and 4 months for the high-risk group. These results are based on data from a limited number of patients, i.e., patients evolved to AML of whom data on time for progression to AML were known (21 of 49 patients; 12 in the INT-1-risk, 6 in the INT-2-risk and 3 in the high-risk group).
In addition, of these 177 patients, 124 patients (70%) died of whom 43 (35%) died of leukemia. Proportions of patients who died of AML in relation to their initial prognostic risk group were 35% for the low-risk group, 29% for the INT-1-risk group, 32% for the INT-2-risk group and 67% for the high-risk group.
Discussion
Despite some differences in age and cytogenetics of the Leuven cases in comparison to the IPSS workshop cases, the IPSS stratified our patients effectively into four prognostic subgroups with significantly different (P -0.0001) median survivals.
Comparison of the IPSS to the FAB-proposal showed the ability of the IPSS to discriminate between patients within one specific FAB-subgroup, confirming the results of the IPSS workshop and of a Japanese group which recently applied the IPSS successfully on a group of40RA patients [17] .
The higher sensitivity of the IPSS compared to the FAB-system can be explained by the fact that the IPSS combines clinical and morphological features with cytogenetic abnormalities. The prognostic importance of cytogenetic abnormalities in MDS has been demonstrated in earlier studies [7, 18] . Our study confirms the significantly different survival expectation of patients stratified into the three cytogenetic categories as defined by the IPSS workshop ( Table 2) : patients of the cytogenetic poor group had significantly shorter survivals than those of the cytogenetic intermediate and good groups (data not shown). Our data on the evolution to AML differ somewhat from the results shown by the IPSS workshop as we could not demonstrate a lower risk of death from AML for the low risk group compared to that for both intermediate groups.
As shown by other studies [2-4, 14, 19] , age turned out to be a prognostic important parameter with a better survival for patients younger than 60. Moreover we could demonstrate that the IPSS has a better discriminatory power when applied to this subgroup of patients as in the elderly group age related factors contribute relatively more to the final outcome and diminish the absolute impact of disease related factors on prognosis.
Finally, the survival rates for our cases were better than those reported in the IPSS study. This discrepancy can be explained by the overall younger age of patients included in our study as by the large number of cases diagnosed after 1 January 1991. Indeed, dividing our population into two groups diagnosed before and after 1 January 1991, revealed different survival rates: the latter group showed substantially better survival expectations while the median age was similar for both groups. The overall improvement of supportive therapy during the last decade may be responsible for this finding. The relative success of antileukemic treatment in MDS or altered referral patterns might be other possible explanations.
Estey et al. [20] in their study on the validity of the IPSS, reported much shorter survivals for each of the patient categories. However, several of the M.D. Anderson patients may have had evolving AML in stead of MDS [21] , reflecting the diversity in the implementation of the FAB-criteria by different centres and the difficulties in making a diagnosis on cytology alone, as it is prescribed by the FAB-proposal. In this respect, histological examination of bone marrow biopsies may be of help. Presence of abnormal localization of immature precursors (ALIP) [15] and immunohistochemical staining for CD34 [22] , as evaluated in bone marrow biopsies, were previously found to have prognostic importance but were not investigated by the workshop. Our future perspectives are to correlate ALIP and CD34 positivity in bone marrow biopsies of MDS patients to their prognosis as determined by the IPSS. Although the IPSS seems to be an effective method for predicting survival or AML evolution in MDS patients, further studies are necessary to proof its validity in the design and the analysis of therapeutic trials. In view of this, the IPSS has certain limitations. Firstly, the IPSS requires cytogenetic data which are not always available at the time of diagnosis due to unsuccessful karyotyping. Secondly, it is not clear whether the IPSS will predict for the response to treatment. While the percentage of bone marrow blasts and the karyotype were found to be two important factors affecting relapse rate and disease-free survival after different therapy strategies in MDS patients [23, 24] , a recent phase II study could not demonstrate a correlation between IPSS score and the response rate to treatment with granulocyte-colony stimulating factor and erythropoietin [25] . Finally, the choice of therapy can not exclusively be based on prognosis but will also depend on the age and the performance status of the patient, since curative treatment modalities for MDS are aggressive.
In conclusion, we confirm the effectiveness of the IPSS to stratify MDS patients into distinctive prognostic subgroups, with respect to survival, and demonstrated its higher discriminatory power compared to the FABclassification.
